Predict your next investment

HEALTHCARE | Drug Development
rainthera.com

See what CB Insights has to offer

Founded Year

2017

Stage

IPO | IPO

Total Raised

$82.36M

Date of IPO

4/23/2021

Market Cap

0.37B

Stock Price

13.21

About Rain Therapeutics

Rain Therapeutics (NASDAQ: RAIN) is a biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression.

Rain Therapeutics Headquarter Location

8000 Jarvis Ave Suite 204

Newark, California, 94560,

United States

510-953-5559

Latest Rain Therapeutics News

Rain Therapeutics to Present at IASLC 2021 World Conference on Lung Cancer and Participate in Panel Discussion at Citi 16th Annual Biopharma Virtual Conference

Sep 1, 2021

Citi 16th Annual Biopharma Virtual Conference Targeted Oncology Panel Discussion Date: Friday, September 10, 2021 Time: 6:45 – 7:30 a.m. PT A copy of the poster and a replay of the panel discussion will be available by visiting the " Events & Presentations " section of the Rain website after the conclusion of the presentations and will be archived on the Rain website for 30 days. Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. Media Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Rain Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rain Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Rain Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Rain Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.